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Dermoscopy and Overdiagnosis of Melanoma In Situ
Kaitlin L. Nufer, BBiomedSci; Anthony P. Raphael, PhD; H. Peter Soyer, MD, FACD, FAHMS
In this issueof JAMADermatology, Lallas et al1 state that “our
goal today is to detect melanoma, if possible, before it be-
comes invasive.” Given the challenges related to the early de-
tectionofmelanoma facedby
clinicians and patients alike,
this goal canonlybeachieved
through further improving
clinical training of clinicians, allied health care workers, and
consumersalike, combinedwithheightened individual aware-
ness and advanced imaging technologies.2
Recently at the 2017World Congress of Melanoma in Bris-
bane,Australia,WolfgangWeyers,MD,also commented that in
regard to the detection of melanoma, “the earlier the better;
however, this is only true if themelanoma can be recognized.”
Weyer’s statement raises 2 questions that have seenmuch de-
bate in the scientific andmedical communities. The first ques-
tion is, how early is too early? From a clinical perspective, the
smaller themalignantneoplasm, thebetter theoutcomes.How-
ever, in an era of “cancer overdiagnosis” and tighter govern-
ment spending, screening programs and improved diagnostic
approaches are scrutinized for early detection of indolent le-
sions. This leads to the second question, is it a melanoma? In
this context, the recent article by Elmore et al3 highlights the
difficulties in addressing this question at the histopathologic
level. In particular, early-stage disease (melanoma in situ) re-
sulted indiagnosis thatwasneither reproduciblenor accurate.
For example, of 187 pathologists, only 40%made a diagnosis
ofmelanoma in situ in agreementwith the referencediagnosis
(obtained from 3 dermatopathologists).3
The significance of the findings byElmore et al3 in relation
tomelanomamanagementisthatthemajorityofcasesdiagnosed
within the “melanoma epidemic” are disproportionally attrib-
utedtomelanomainsitu.Althoughnoninvasiveitself,melanoma
in situ results in an increased risk of invasivemelanoma4,5 and
increasedriskofseveralothercancers.4Theserisksarenottrivial
and can lead to serious medicolegal consequences if invasive
melanomaweretodevelop,orontheotherendof thespectrum,
lead to increasedanxiety, excisions, andcost topatients forpo-
tentially benign lesions.
Since its clinical implementation in the late 1980s,dermos-
copy has significantly enhanced diagnostic accuracy over
naked-eyeexamination6-8 andcomplementedhistopathologic
analysis throughwhole-lesionmorphologicalcharacterization.9
Melanomasaredetectedanddiagnoseddermoscopicallyusing
various guidelines including, but not limited to, theABCD rule
(asymmetry, irregularborders,>1orunevendistributionofcolor,
ora large[>6mm]diameter),7-pointchecklist,Menziesmethod,
ortheACrule(asymmetry,colorvariation).10Althougheffective,
manyof thestudiesestablishingthesecriteriaconsistedof later-
stage invasivemelanomas andas such fall short for early-stage
“dermoscopically featureless”11melanoma, particularlymela-
noma insitu.Thesedifficult-to-diagnosemelanomashighlight
a problematic shortfall in dermoscopic criteria,making identi-
fication and diagnosis challenging.
ThestudybyLallasandcolleagues1addressesthelimitations
of currentdermoscopycriteriaby investigating theaccuracyof
melanomacriteria specifically for thediagnosisofmelanomain
situ. The authors identified 5 dermoscopic criteria as positive
markers formelanoma insitucomparedwithcommonlyoccur-
ringbenignpigmented lesions.1 Lallas et al1 believe that imple-
mentationof their criteriawill have thepotential to reduce the
burden on patients, clinicians, and the health care system (eg,
anxiety aroundmetastasis and resulting treatment,medicole-
galramificationsfromwrongdiagnosisandcost).However,given
today’s controversy around early detection and overdiagnosis
of clinically indolent lesions, implementation of these refined
dermoscopiccriteria intonewguidelinesandscreeningprograms
should address thosewho benefitmost.
One potential benchmark that is also often raised in the
overdiagnosis debate is the number needed to biopsy. The re-
cent article by Lott et al12 determined that more than 90% of
biopsies were attributed to benign or low-risk lesions (Mela-
nocytic Pathology Assessment Tool and Hierarchy for Diag-
nosis class I and II), with melanoma in situ (class III) contrib-
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uting 4.5%.However,with the influence of “diagnostic drift,”
pressure ofmedical liability, andvariability inhistopathologi-
caldiagnosis, theaccuratediagnosisofmelanomainsitu iscriti-
cal for appropriate management. Given that dermoscopy has
been shown to reduce the number of biopsies by improving
the benign tomalignant ratio,13 it further emphasizes the im-
portance of the study by Lallas et al1 in establishing optimal
criteria for early equivocal lesions.
The individualswhowill benefitmost fromimproveddiag-
nostic accuracy are thosewithmultiple nevi and a personal or
family history ofmelanoma. It is not feasible from a patient or
practical perspective to excise everynevus, so accuratenonin-
vasivediagnostic toolsareneeded.TherecentSpecialReportby
ThomasandPuig14discusses thebenefitsandchallengesofder-
moscopyforearlydetectionofmelanomainhigh-risk individu-
als. Of note is the role that digital dermoscopy plays in contin-
uedsurveillance:“comparisonsofgoodquality [accurateandre-
producible] imagesprovideadditionalopportunities tomakean
accuratediagnosis of an initially featurelessmelanoma.”14 Yet,
evenwiththeestablishedbenefits,dermoscopyuptakeandutil-
ity still faces challenges. This is in part due to a perceived com-
plexityofdermoscopic criteria inhibiting awillingness of clini-
cians to become qualified and experienced with routine
dermoscopy.14 Therefore, studies similar to that byLallas et al1
areneeded to refineandsimplifydermoscopic criteria andpro-
mote its clinical utility for earlymelanomadetection.
While thedebate of overdiagnosiswill continue, the anxi-
ety around underdiagnosis remains from both a medicolegal
andahumanpointofview.The integrationofdermoscopy (and
total-body photography15) within screening programs, par-
ticularly forhigh-risk individuals, is theoptimalmethod tode-
tect and monitor for melanoma in situ. However, dermos-
copy is just one, albeit essential, weapon in the battle against
melanoma, and we foresee that a holistic approach incorpo-
rating current risk assessment tools, genetic profiling, total-
body photography, and sequential dermoscopy imaging
will play a crucial role in early melanoma detection and
management.2 The tools for achieving the goal of Lallas et al1
of detecting noninvasive melanoma are available; it is just a
matter of putting them into our daily practice.
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JAMADermatology—The Year in Review, 2017
June K. Robinson, MD
JAMA Dermatology continues to enhance our digital pres-
ence, which serves to inform
physicians and the public
about advances in treatment
of skinconditions.The journal content isavailableonlineahead
of print, and we connect with our readers via the electronic
table of contents and through social media. Each weekly on-
line issue of the journal offers an article free to be down-
loaded for 1 week; thus, the public has free access to selected
articles.Our reachextended to 3.4millionpeople in 2017with
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